Reason for request
Extension of indication
Clinical Benefit
Clinical Added Value
| moderate |
LUCENTIS 10 mg/mL, solution for injection provides a moderate improvement in actual benefit (level III) in terms of efficacy in comparison with VISUDYNE in the treatment of visual impairment due to choroidal neovascularisation secondary to pathologic myopia. |
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
sk45aGbekh7qmd3N
Listen
